Professor Marc Pellegrini and his team have discovered that a drug called birinapant, designed to target and kill cancer cells, may also be effective in killing cells infected with Human Immunodeficiency Virus (HIV).
With generous support for a second year from the Phyllis Connor Memorial Trust, managed by Mr Norman Bourke and Equity Trustees Limited, Professor Pellegrini and his team will be able to carry out essential pre-clinical tests.
“A philanthropic grant at the final (pre-clinical) stage of a research study is crucial as there is an absence of funding opportunities to get a project completed and ‘over the line,’” Professor Pellegrini said.